<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>MEDPLUS</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">MEDPLUS</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="medplus-health-services-limited" class="section level1">
<h1>Medplus Health Services Limited</h1>
<p><a href="/reports01/index/industry/rp-PharmacyRetail.html">Pharmacy Retail</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.MEDPLUS.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<div id="comprehensive-analysis-of-medplus-health-services-limited-mdbox" class="section level9">
<p class="heading"><strong>Comprehensive Analysis of MedPlus Health Services Limited (MDBOX)</strong></p>
<hr />
<div id="overview-business-model" class="section level12">
<p class="heading"><strong>1. Overview &amp; Business Model</strong></p>
<p><strong>Company:</strong> <em>MedPlus Health Services Limited</em><br />
<strong>BSE Scrip Code:</strong> 543427 | <strong>NSE Symbol:</strong> MEDPLUS<br />
<strong>Industry:</strong> Healthcare Retail &amp; Diagnostics<br />
<strong>Core Segments:</strong><br />
- <strong>Retail (Pharmacies):</strong> Chain of pharmacy stores across India under ‚ÄúMedPlus.‚Äù<br />
- <strong>Diagnostic Services:</strong> Laboratory chain ‚ÄúMedPlus Diagnostics.‚Äù<br />
- <strong>Others:</strong> Includes insurance broking, employee benefits trust, and other ventures.</p>
<p>The company operates an integrated healthcare delivery platform: retail pharmacies, diagnostics (lab testing), and supportive services.</p>
<hr />
</div>
</div>
<div id="key-financial-highlights-quarter-ended-september-30-2025-q2-fy26" class="section level6">
<h6>üîç <strong>Key Financial Highlights (Quarter Ended September 30, 2025 ‚Äì Q2 FY26)</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26 (Unaudited)</th>
<th>YoY Change</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Revenue from Operations</strong></td>
<td>‚Çπ16,793.29 Cr</td>
<td>+6.5% (vs ‚Çπ15,761.72 Cr)</td>
</tr>
<tr class="even">
<td><strong>Net Profit After Tax (Standalone)</strong></td>
<td>‚Çπ156.31 Cr</td>
<td>+101.7% YoY</td>
</tr>
<tr class="odd">
<td><strong>Net Profit After Tax (Consolidated)</strong></td>
<td>‚Çπ555.02 Cr</td>
<td>+43.4% YoY</td>
</tr>
<tr class="even">
<td><strong>Earnings Per Share (Basic EPS - Consolidated)</strong></td>
<td>‚Çπ4.63</td>
<td>+42.7% YoY</td>
</tr>
<tr class="odd">
<td><strong>Total Assets</strong></td>
<td>‚Çπ35,722.16 Cr</td>
<td>+7% QoQ</td>
</tr>
<tr class="even">
<td><strong>Cash &amp; Cash Equivalents</strong></td>
<td>‚Çπ2,097.80 Cr</td>
<td>+144% QoQ</td>
</tr>
<tr class="odd">
<td><strong>Operating Cash Flow (H1 FY26)</strong></td>
<td>‚Çπ3,133.37 Cr</td>
<td>+14.9% YoY</td>
</tr>
<tr class="even">
<td><strong>IPO Proceeds Remaining Unutilized:</strong></td>
<td>‚Çπ423.50 Cr</td>
<td>Invested in fixed deposits</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üí° <em>Strong revenue growth, expanding margins, and robust operating cash flows signal improving operational efficiency.</em></p>
</blockquote>
<hr />
</div>
<div id="headwinds-risks" class="section level6">
<h6>üå™Ô∏è <strong>Headwinds &amp; Risks</strong></h6>
<div id="diagnostic-segment-under-pressure" class="section level9">
<p class="heading">1. <strong>Diagnostic Segment Under Pressure</strong></p>
<ul>
<li>The diagnostics segment reported:
<ul>
<li><strong>Quarterly EBIT (operating profit): ‚Çπ2.07 Cr</strong></li>
<li><strong>Loss of ‚Çπ76.18 Cr (H1 FY25 ‚Üí H1 FY26)</strong> ‚Äì despite revenue growth (‚Çπ635.40 Cr vs ‚Çπ525.57 Cr).</li>
</ul></li>
<li><strong>Negative Contribution to Group Results:</strong> Segment lost ‚Çπ3.328 Cr YoY (implied).</li>
<li>High fixed costs (infrastructure, lab techs, machines) and intense competition pressure margins.</li>
</ul>
<blockquote>
<p>‚ùó <strong>Risk:</strong> May need to restructure or slow expansion until profitability stabilizes.</p>
</blockquote>
<hr />
</div>
<div id="limited-auditor-review-scope" class="section level9">
<p class="heading">2. <strong>Limited Auditor Review Scope</strong></p>
<p>Auditors (B S R &amp; Co) noted:</p>
<ul>
<li><strong>Did Not Review 10 Subsidiaries</strong> with total assets of:
<ul>
<li><strong>‚Çπ1,284.61 Cr + ‚Çπ813.14 Cr = ‚Çπ2,097.75 Cr</strong></li>
</ul></li>
<li><strong>Revenue Before Consolidation Adjustments from Unreviewed Entities:</strong>
<ul>
<li>Combined ‚Çπ1,855.75 Cr (Q) + ‚Çπ653.61 Cr = <strong>‚Çπ2,509.36 Cr</strong> ‚Äî ~15% of reported revenue.</li>
</ul></li>
</ul>
<blockquote>
<p>‚ö†Ô∏è While auditors <strong>did not modify</strong> their report and relied on other auditors‚Äô work, limited review scope creates <strong>transparency risk</strong> and potential concentration of key accounting estimates off-screen.</p>
</blockquote>
<hr />
</div>
<div id="high-leverage-in-balance-sheet" class="section level9">
<p class="heading">3. <strong>High Leverage in Balance Sheet</strong></p>
<ul>
<li><strong>Total Lease Liabilities (Current + Non-Current):</strong> ‚Çπ12,821.14 Cr
<ul>
<li>‚âà <strong>35.9% of Total Assets</strong> (‚Çπ35,722 Cr)</li>
</ul></li>
<li><strong>Right-of-Use (RoU) Assets:</strong> ‚Çπ10,140.95 Cr (stores, facilities under lease)</li>
<li>Lease-heavy business model due to reliance on <strong>retail pharmacy outlets</strong> leased across cities.</li>
</ul>
<blockquote>
<p>‚ö†Ô∏è High lease obligations = exposure to rent renegotiations and lower operating flexibility.</p>
</blockquote>
<hr />
</div>
<div id="regulatory-risks-in-related-party-transactions" class="section level9">
<p class="heading">4. <strong>Regulatory Risks in Related-Party Transactions</strong></p>
<ul>
<li><strong>Resolution No.¬†4</strong> passed to approve:
<ul>
<li><strong>Material RPTs with Optival Health Solutions Private Limited</strong>, a subsidiary where IPO funds were partly invested.</li>
</ul></li>
<li>Although approved (&gt;99% in favor), continued RPTs may attract <strong>SEBI scrutiny</strong> over governance or misuse of group structure.</li>
</ul>
<blockquote>
<p>‚ö†Ô∏è While not inherently negative, frequent RPTs in capital-intensive subsidiaries require disclosure vigilance.</p>
</blockquote>
<hr />
</div>
<div id="governance-concerns-in-voting-disclosure" class="section level9">
<p class="heading">5. <strong>Governance Concerns in Voting Disclosure</strong></p>
<ul>
<li>In <strong>Resolution No.4 (RPT approval)</strong>:
<ul>
<li><strong>Total votes polled:</strong> 46.7M shares (vs 119.8M outstanding) ‚Üí ~39% participation.</li>
<li><strong>6.1M invalid votes</strong>, all from <strong>non-promoter institutions</strong>.</li>
</ul></li>
<li><strong>No promoter vote</strong> ‚Äî but promoters own ~40% (inferred from shareholder data).</li>
<li><strong>Promoters abstained or didn‚Äôt vote</strong> ‚Äî raised concerns about conflict of interest.</li>
</ul>
<blockquote>
<p>‚ö†Ô∏è While resolution passed easily, low promoter participation in sensitive RPTs may reflect <strong>poor internal governance culture</strong>.</p>
</blockquote>
<hr />
</div>
</div>
<div id="tailwinds-growth-opportunities" class="section level6">
<h6>üå¨Ô∏è <strong>Tailwinds &amp; Growth Opportunities</strong></h6>
<div id="strong-retail-growth-momentum" class="section level9">
<p class="heading">1. <strong>Strong Retail Growth Momentum</strong></p>
<ul>
<li><strong>Retail Revenue (Q2 FY26): ‚Çπ16,456.41 Cr</strong> (+6.3% YoY)</li>
<li><strong>Retail EBIT: ‚Çπ592.04 Cr</strong> (+24.3% YoY)</li>
<li>Operating profit margin in retail: <strong>3.59%</strong> ‚Üí improving from <strong>3.15% YoY</strong></li>
</ul>
<blockquote>
<p>‚úÖ <strong>Tailwind:</strong> Retail pharmacy remains the <strong>profit engine</strong>, with scale and brand power driving efficient store economics.</p>
</blockquote>
<hr />
</div>
<div id="ipo-fund-utilization-financial-stability" class="section level9">
<p class="heading">2. <strong>IPO Fund Utilization &amp; Financial Stability</strong></p>
<ul>
<li><strong>IPO raised:</strong> ‚Çπ13,983 Cr (net of expenses)</li>
<li><strong>As of Sept 30, 2025: ‚Çπ5,365.83 Cr used</strong>
<ul>
<li>Fully deployed ‚Çπ4,671.7 Cr into <strong>Optival</strong>, a subsidiary (pharma distribution)</li>
<li>‚Çπ694.13 Cr in corporate purposes</li>
</ul></li>
<li><strong>Unutilized IPO funds:</strong> ‚Çπ423.5 Cr ‚Üí parked in <strong>safe FDs</strong></li>
</ul>
<blockquote>
<p>‚úÖ <strong>Sign of prudent capital management</strong>; strong balance sheet buffers for M&amp;A or downturns.</p>
</blockquote>
<hr />
</div>
<div id="robust-cash-flows-capital-recycling" class="section level9">
<p class="heading">3. <strong>Robust Cash Flows &amp; Capital Recycling</strong></p>
<ul>
<li><strong>H1 Operating Cash Flow:</strong> ‚Çπ3,133.37 Cr (+14.9% YoY)</li>
<li><strong>Low Capex:</strong> ‚Çπ427.71 Cr (vs ‚Çπ290.71 Cr prior H1)</li>
<li>Used for <strong>rolling deposits</strong>; maturity inflow: ‚Çπ4,805 Cr</li>
</ul>
<blockquote>
<p>‚úÖ Cash is being efficiently cycled between operations, deposits, and working capital.</p>
</blockquote>
<hr />
</div>
<div id="digital-adoption-governance-transparency" class="section level9">
<p class="heading">4. <strong>Digital Adoption &amp; Governance Transparency</strong></p>
<ul>
<li>AGM conducted via <strong>video conferencing</strong></li>
<li>E-voting used:
<ul>
<li><strong>357 remote voters</strong>, 35 at AGM ‚Äî transparent &amp; SEBI-compliant</li>
<li>High approval rate (~99.99%) across all resolutions ‚Üí strong shareholder confidence</li>
</ul></li>
<li>Statutory disclosures timely and detailed</li>
</ul>
<blockquote>
<p>‚úÖ Signals <strong>good corporate governance</strong> and investor engagement.</p>
</blockquote>
<hr />
</div>
<div id="segment-diversification-strategy" class="section level9">
<p class="heading">5. <strong>Segment Diversification Strategy</strong></p>
<ul>
<li>Despite diagnostics losses, revenue up <strong>21% YoY (H1)</strong></li>
<li>Investment in scalable lab infrastructure positions MedPlus for future volume growth</li>
<li>Long-term play: <strong>pharma + diagnostics</strong> bundles = ecosystem advantage</li>
</ul>
<blockquote>
<p>‚úÖ Potential for <strong>cross-sell and sticky customer relationships</strong> once scale improves.</p>
</blockquote>
<hr />
</div>
<div id="strong-shareholding-support" class="section level9">
<p class="heading">6. <strong>Strong Shareholding Support</strong></p>
<ul>
<li><strong>Promoters hold 48.3M shares (40.27% of total)</strong></li>
<li>Reappointment of <strong>Whole-Time Director approved with 99.99% support</strong> ‚Üí board stability</li>
<li>Institutional voting strong: &gt;99.9% support in most resolutions</li>
</ul>
<blockquote>
<p>‚úÖ Suggests <strong>strategic clarity and no internal discord</strong></p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6>üìà <strong>Growth Prospects</strong></h6>
<table>
<colgroup>
<col width="33%" />
<col width="66%" />
</colgroup>
<thead>
<tr class="header">
<th>Catalyst</th>
<th>Potential Impact</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Expansion in Tier 2/3 Cities (Pharma + Diagnostics)</strong></td>
<td>Untapped market; lower competition; high margin potential</td>
</tr>
<tr class="even">
<td><strong>Integration of Optival Distribution Network</strong></td>
<td>Supply chain control, cost saving, better inventory</td>
</tr>
<tr class="odd">
<td><strong>Cross-Selling Across Segments</strong></td>
<td>Bundle prescriptions + tests + insurance ‚Üí higher LTV</td>
</tr>
<tr class="even">
<td><strong>Digital Health Play (MedPlus App, Tele-consultation)</strong></td>
<td>Future upside beyond brick-and-mortar</td>
</tr>
<tr class="odd">
<td><strong>Selective M&amp;A (Diagnostic chain acquisition)</strong></td>
<td>Faster footprint conversion</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üí° <strong>Outlook:</strong> MedPlus is <strong>transitioning from pure pharmacy play</strong> to an <strong>integrated healthcare provider</strong> ‚Äî positioning it for long-term resilience.</p>
</blockquote>
<hr />
</div>
<div id="summary-investment-thesis" class="section level6">
<h6>üîö <strong>Summary: Investment Thesis</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>üìà Growth</strong></td>
<td><strong>High</strong> ‚Äì driven by retail momentum and diagnostics expansion</td>
</tr>
<tr class="even">
<td><strong>üí™ Financial Health</strong></td>
<td><strong>Strong</strong> ‚Äì healthy cash flows, low debt (barring lease liabilities), IPO cash buffer</td>
</tr>
<tr class="odd">
<td><strong>üõ°Ô∏è Risks</strong></td>
<td><strong>Moderate to High</strong> ‚Äì leases, diagnostic losses, RPTs, auditor review gaps</td>
</tr>
<tr class="even">
<td><strong>‚öñÔ∏è Valuation Signal</strong></td>
<td>EPS up &gt;40% YoY; stock appears growth-priced; monitor P/E</td>
</tr>
<tr class="odd">
<td><strong>üìä Key Risks Summary</strong></td>
<td>1. Diagnostics not profitable yet<br>2. Lease liability overhang<br>3. Partial auditor review<br>4. Related-party transparency<br>5. Market competition in urban diagnostics</td>
</tr>
<tr class="even">
<td><strong>üéØ Tailwinds Summary</strong></td>
<td>1. Strong retail performance<br>2. Healthy cash generation<br>3. Prudent capital use<br>4. Ecosystem integration<br>5. High shareholder approval &amp; governance</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="conclusion-cautiously-optimistic" class="section level6">
<h6>‚úÖ <strong>Conclusion: Cautiously Optimistic</strong></h6>
<p><strong>MedPlus Health Services Limited</strong> is a <strong>growth-oriented healthcare retailer</strong> with solid financials and brand presence. The <strong>core pharmacy business is thriving</strong>, generating strong cash flows and profitability.</p>
<p>However, <strong>diagnostics is a drag</strong>, and investor attention must remain on <strong>operating turnaround</strong> in that segment.</p>
<p>While <strong>governance is largely robust</strong>, <strong>partial auditor review and RPT risks</strong> need ongoing monitoring. The company‚Äôs <strong>transition to a holistic health partner</strong> gives it long-term upside, but near-to-medium-term profits will rely on <strong>margin discipline and capex control</strong>.</p>
<blockquote>
<p>üü¢ <strong>Verdict: Buy on dip with long-term horizon</strong>, provided diagnostics show path to breakeven and capital allocation remains prudent.</p>
</blockquote>
<hr />
</div>
<div id="key-monitorables-going-forward" class="section level6">
<h6>üîî Key Monitorables Going Forward</h6>
<ol style="list-style-type: decimal">
<li><strong>Profitability of Diagnostics Segment</strong> ‚Äì Target EBIT break-even by FY27<br />
</li>
<li><strong>Lease Liabilities Trend</strong> ‚Äì Monitor expansion velocity vs cash flow sustainability<br />
</li>
<li><strong>Utilization of Remaining IPO Funds</strong> ‚Äì Strategic deployment visibility<br />
</li>
<li><strong>Auditor Review Scope</strong> ‚Äì Future coverage of key subsidiaries<br />
</li>
<li><strong>E-voting &amp; RPT Disclosures</strong> ‚Äì Ensure consistent high promoter engagement<br />
</li>
<li><strong>Same-Store Sales Growth (SSSG)</strong> ‚Äì Indicator of retail health</li>
</ol>
<hr />
<p>üîê <strong>Bottom Line:</strong><br />
<em>MedPlus has evolved beyond a pharmacy chain into India‚Äôs emerging primary care hub. It carries execution risk, but with disciplined growth, could become a top-tier healthcare play.</em></p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
